Patient Leaflet Information

Home
Patient Leaflet Information

Important: NHS Screening programmes

Full list of screening programmes available

Important: Breast Screening

Important: Bowel cancer screening

Important: Cervical Screening

Important: me + my medicines

Me and My Medicines’ is a campaign led by patients and supported by clinical staff to help people raise concerns and use their medicines better. This will help everyone benefit from more effective and safer care.

Rare side effects associated with certain medications

SGLT-2 inhibitors

and rare side effects in type 2 diabetes - Please click here to read more

Medications included are: Canagliflozin, ,Dapagliflozin, Empagliflozin, Ertugliflozin.

ADHD

For information about ADHD prescribing, including a Frequently Asked Questions section please click here.

Prescribing benzodiazepines or sedatives

After careful consideration, we will no longer prescribe benzodiazepines or sedatives (such as diazepam) for patients experiencing fear of flying or medical procedures. Many other GP practices have adopted similar policies. Please click here to read more on this decission and where to get support.

Update on Access to Tirzepatide (Mounjaro) for Weight Management

On 23 June 2025, it was announced that people living with obesity will begin to access tirzepatide (Mounjaro) for weight loss in primary care settings across England.

However, this national announcement does not mean that prescriptions will be made available immediately to all eligible patients at GP practices.

Weight management services are commissioned locally by each area's Integrated Care Board (ICB), meaning access to treatments like tirzepatide will differ between regions. In Mid and South Essex, access to tirzepatide will initially be through specialist weight management services only.

At this time, tirzepatide will not be available via GP practices in Mid and South Essex. Access through primary care is not expected to begin until later in 2025.

This medication is prioritised for people with the highest clinical need and those living with obesity who also suffer from multiple obesity-related health conditions and stand to benefit the most from treatment.

👉 Find out more about eligibility and access to tirzepatide in Mid and South Essex by visiting the official NHS page: